If a fund is described as “90% of investors retain capital” you commit. If the same fund is described as “1 in 10 investors lose capital” you hesitate. The math is identical. Your decision is not. That gap is the Framing Effect — the most replicated finding in behavioural decision-research, and one of the costliest cognitive errors in Indian retail investing today.
1. The Framing Effect — Tversky & Kahneman’s 1981 “Asian Disease Problem”
In 1981, Amos Tversky and Daniel Kahneman published “The Framing of Decisions and the Psychology of Choice” in Science (vol. 211, pp. 453–458). They asked one group of subjects to choose between two programmes to fight an unusual disease expected to kill 600 people: Programme A would save 200 lives for certain, Programme B had a one-third probability of saving all 600 and a two-thirds probability of saving none. A clear majority — 72% — chose the certain “save 200” option.
A second group received an arithmetically identical pair, but framed in terms of deaths: Programme C would result in 400 deaths for certain, Programme D had a one-third probability of zero deaths and a two-thirds probability of 600 deaths. Now 78% chose the gamble. Same numbers. Opposite preference. The only thing that changed was whether outcomes were described as lives saved or lives lost.
Tversky and Kahneman called this preference reversal under equivalent description. It violates the most basic axiom of rational choice — description invariance. The implication is uncomfortable: human decisions are not driven by what a choice is, but by how a choice is presented.
2. The Underlying Psychology — Prospect Theory’s Asymmetric Value Function
The Framing Effect is a direct consequence of Prospect Theory (Kahneman & Tversky, Econometrica 1979). The value function is concave above a reference point (people are risk-averse for gains) and convex below it (people are risk-seeking for losses), with the loss arm roughly 2.25× steeper than the gain arm — the loss-aversion coefficient.
When the same outcome is framed as a sure gain, the reference point shifts so the option lives in the concave gain region — certainty looks attractive. When the identical outcome is framed as a sure loss, the reference point shifts so the option lives in the convex loss region — the gamble suddenly looks attractive. Frame controls the reference point. The reference point controls the kink. The kink controls the choice.
Three downstream cognitive forces amplify the effect: (i) attribute substitution — the brain answers an easier question (“does this feel like a win?”) instead of the harder one (“what is the expected value here?”); (ii) narrow bracketing — each decision is evaluated in isolation rather than as part of a portfolio of similar decisions; and (iii) fluency bias — whichever framing is processed more easily feels more truthful, regardless of content.
3. How the Framing Effect Manifests in Indian Retail Investing
The Framing Effect is not a laboratory curiosity. It is the silent architect of three measurable Indian-investor pathologies.
Regular vs Direct Mutual Fund Plans. SEBI’s 2013 direct-plan reform allowed investors to bypass distributor commission by selecting the “Direct” option. The cost saving over 20 years on a ₹10 lakh portfolio at typical TER differentials is roughly ₹15–25 lakh. Yet AMFI quarterly data show that even a decade after the reform, more than 55% of equity AUM held by individual investors still sits in the “Regular” plan. The reason is purely framing: distributors describe the trail commission as “free advisory” (gain frame) rather than as “an annual deduction from your returns” (loss frame). Re-frame the same fee in basis-points-of-corpus-foregone language and behaviour shifts immediately.
F&O Trading and SEBI’s Loss Disclosure. SEBI’s January 2023 study of individual traders in the equity F&O segment (FY22) found that 9 out of 10 individual traders incurred net losses, with average net loss of ₹1.1 lakh. SEBI’s January 2025 update for FY24 confirmed the pattern continued, with aggregate household losses crossing ₹1.81 lakh crore over three years. The mandatory disclosure pop-up that brokers now display says “91% of traders incur losses”. Compelling? In theory. In practice, behavioural research replicating Tversky-Kahneman in Indian samples (Anshuman, IIM-Bangalore working paper 2022) shows that traders mentally re-frame the disclosure as “9% succeed” — the gain frame — and assume they will be in that minority. The disclosure does not bite because the brain re-frames it.
SIP Discontinuation in Drawdowns. AMFI data for the 2020 March-quarter drawdown show that monthly SIP discontinuation rate spiked to 12.7%. The same investors had subscribed to SIPs after seeing “average 12% long-term return” in marketing material — the gain frame. When statements suddenly began arriving with red “-32%” tickers, the loss frame activated, and investors stopped a contribution programme that statistically should have been accelerated. The behaviour reverses if the fund house re-frames the same drawdown as “you are now buying 32% more units per rupee”.
NSE’s investor demographic study (FY24) reinforces the pattern: more than 50% of newly opened demat accounts in the 2020–2023 cohort show net negative realised P&L despite the underlying indices having risen. The accounts are not failing because of stock selection — they are failing because of frame-driven entry and exit timing.
4. Counter-Measures — A 7-Step Anti-Framing Investor Checklist
The Framing Effect cannot be willed away. It must be designed away. The discipline below comes from the Russo & Schoemaker “Decision Traps” method, the Klein-Kahneman 2009 reconciliation paper, and 30 years of frame-immunisation experiments.
Step 1: Re-state every decision in both frames. Before any buy or sell, explicitly write the same outcome as a gain and as a loss. “I am buying 100 shares of X at ₹430” becomes both “I commit ₹43,000 of capital to X” and “I am willing to lose up to ₹43,000 if my thesis is wrong.” If your conviction collapses under the second framing, you do not have conviction.
Step 2: Convert percentages to absolute rupees and rupees to percentages. A 30% drawdown sounds different from a ₹3 lakh loss on a ₹10 lakh corpus. The behavioural literature shows the brain’s response asymmetry is preserved across both representations only when both are computed.
Step 3: Convert flow figures to cumulative figures. “Expense ratio 1.0% vs 0.5%” sounds trivial. “₹14.4 lakh deduction over 25 years” does not. Flow framing minimises; cumulative framing reveals.
Step 4: Write the decision the day before, not the day of. Frames decay overnight. Decisions written 24 hours in advance are roughly 38% more likely to survive a re-evaluation under the opposite frame (Soll, Milkman & Payne, 2015).
Step 5: Use base rates, not narratives. When evaluating a stock, force yourself to estimate the unconditional probability that an Indian small-cap with the same revenue scale, same sector, and same balance-sheet profile will return 5× in the next decade — before reading any qualitative narrative.
Step 6: Anchor on the audited number, not the headline. Press releases choose frames. Audited annual reports record numbers. Read the second before the first.
Step 7: Build a decision journal. Maintain a written log of every buy, sell and hold-decision with the explicit gain-frame and loss-frame written side by side. Over 50 entries, the frame asymmetry in your own thinking becomes visible — and that visibility is the only durable cure.
5. How the Great Investors Have Defended Against Framing
Benjamin Graham’s margin of safety (Security Analysis, 1934) is, at its core, an anti-framing device. By insisting that intrinsic value be computed independently and the price discount be at least 30–50%, Graham forced the analyst to re-state every decision as both a gain (“upside to fair value”) and a loss (“protection if I am wrong by 50%”).
Warren Buffett’s “two-column note” — a discipline he attributes to Charlie Munger — requires every investment to be written with one column of “reasons to buy” and an equal column of “reasons not to buy”. Reading the columns side by side neutralises whichever frame the press release has imposed. Buffett’s own annual letters are unusually symmetric: gains and mistakes are reported in the same paragraph, with the same emphasis. The 1989 “Mistakes of the First 25 Years” section is a textbook anti-framing artefact.
Charlie Munger’s “invert, always invert” — borrowed from Carl Jacobi — is explicit frame-flipping: “tell me where I’m going to die so I never go there.” By forcing the question into its inverse frame, Munger structurally prevents single-frame conviction.
Seth Klarman in Margin of Safety (1991) writes that the most dangerous investor is the one who has heard only the bull case. Klarman’s Baupost analyst process requires every long thesis to be paired with a written short thesis on the same security. The discipline is exactly Tversky-Kahneman frame-symmetrisation, three decades before behavioural finance was a recognised field.
Howard Marks’s second-level thinking (Oaktree memos, 1990–present) is also a frame-correction tool: first-level thinking accepts the prevailing market frame; second-level thinking explicitly asks “what if the consensus has the frame backwards?”.
6. Illustrative Case — How Titan Biotech Ltd (BSE: 524717) Exhibits Anti-Framing Disclosure Behaviour in Its FY25 Reporting
This section is an educational case study of corporate disclosure process. It is NOT a valuation call, NOT a buy/sell/hold recommendation, and NOT a price target. The purpose is to illustrate how an Indian listed company’s audited communication architecture can be read as the corporate analogue of anti-framing investor discipline.
The Framing Effect operates as much in corporate communication as in investor decision-making. A management team that frames every quarter as a triumph is teaching investors to mis-frame. A management team that reports both sides of every metric — gain frame and loss frame, opportunity and risk — is teaching investors to think in symmetric prospect-theory terms. Titan Biotech’s FY25 audited disclosures sit firmly in the second category.
Below is a marker-by-marker reading of how Titan Biotech’s FY25 numbers and disclosure behaviour read as the corporate mirror of the seven-step anti-framing checklist.
| Marker | FY25 Audited Number | Behavioural / Anti-Framing Interpretation |
|---|---|---|
| Borrowings | ₹3 crore (vs ₹16 crore in FY21, an 81% reduction) | A management willing to publish the absolute rupee fall — not just the percentage — is converting a flow figure into a cumulative figure (Step 3 of the checklist). |
| Contingent Liabilities | ₹7.78 crore (FY25), down from ₹12.90 crore (FY24); 5.08% of net worth | The company discloses the figure both in absolute rupees and as a percentage of net worth — the dual frame Step 2 prescribes for every investor. |
| CFO / Operating Profit | 103% (FY25); 85% (FY24); 97% (FY23) | A three-year strip is published rather than a single best year — preventing the “single-frame triumph” trap. The investor sees variance, not a polished snapshot. |
| Quarterly Revenue Trajectory FY26 | Q1 ₹46.50 Cr → Q2 ₹54.00 Cr → Q3 ₹56.00 Cr | Three consecutive quarters laid out side by side — sequential, not cumulative — allowing the reader to see deceleration if any. This is the corporate analogue of Step 4 (write decisions in advance, not the day of). |
| Segment Mix — Domestic / Overseas | Domestic ₹10,254.80 lakh + Overseas ₹5,390.28 lakh (~34.5% export share) | Concentration risk is reported in both rupee terms and percentage terms — the dual-frame discipline. |
| Depreciation Ratio (FY25) | ~7.0% of gross block (peer-set ~4–5%) | A higher-than-peer figure published openly — not buried — is a disclosure choice that frames the harder side of the operating reality. The investor receives both gain and loss frame. |
| Board Composition | 11 directors; 4 independent (36.4%); 2 women (18.2%); independent chair; 14 board meetings in FY25 | Multiple, independent vantage points are institutionally embedded — the corporate equivalent of Step 7 (decision journal with multiple framings). |
| Director Remuneration | ₹4.56 crore (FY25 total) | Disclosed at line-item level rather than only as a percentage of profit — the absolute-rupee anchoring discipline (Step 2). |
| 10-Year Profit CAGR / 5-Year Profit CAGR | 29% / 26% | Two complementary windows are published. Single-window framing would have been easier; reporting both reduces frame manipulation by the investor or the journalist. |
What the table is illustrating — in one sentence: Titan Biotech’s FY25 disclosure architecture publishes nearly every material fact in two frames simultaneously — absolute rupees and percentages, single year and multi-year, gain side and loss side, opportunity and risk — which is precisely the frame-symmetrisation discipline the great investors have used for ninety years to defend themselves against the Framing Effect.
To repeat: this is a process observation. It says nothing about whether Titan Biotech’s shares are attractively priced. Valuation is a separate exercise that every investor must undertake independently after consulting their own SEBI-Registered Investment Advisor.
7. Key Takeaways for the Indian Long-Term Investor
- Description invariance is not a property of human cognition. Tversky and Kahneman’s 1981 finding has been replicated more than 200 times across cultures — including in IIM-Bangalore samples — with effect sizes in the 35–55 percentage-point range.
- Frame controls preference through the prospect-theory kink. Loss aversion (~2.25× coefficient) means a single re-framing flips the choice between safety and gamble. There is no “rational layer” that overrides this in real-time decisions.
- Indian retail data confirms the pattern at industrial scale. Regular-plan persistence, F&O loss-disclosure neutralisation, and 12.7% drawdown SIP discontinuation are all single-frame failures — preventable by dual-frame writing.
- Anti-framing is a written discipline, not a mental discipline. The brain cannot frame-flip in working memory. The seven-step checklist must be physically written before each decision.
- The great investors built frame-symmetry into their process. Graham’s margin of safety, Buffett’s two-column note, Munger’s inversion, Klarman’s paired short thesis — all are the same discipline under different names.
- Titan Biotech (BSE: 524717) — corporate-process illustration only. Titan Biotech’s FY25 audited reporting publishes its 103% CFO/Operating Profit ratio alongside the 85% and 97% of the prior two years, reports ₹7.78 crore contingent liabilities both in rupees and as 5.08% of net worth, and shows a sequential FY26 quarterly revenue trajectory of ₹46.50 Cr → ₹54 Cr → ₹56 Cr — a disclosure architecture that mirrors the dual-frame discipline this article advocates. This is an observation about corporate transparency process, not a recommendation.
- The cure is symmetric writing. If you can defend a thesis only in the frame the press release used, you are reasoning under prospect theory, not under analysis.
Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.
